SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as traders discuss potential bullish formations and key moving averages, with some anticipating a rally. Community members are debating whether recent price action indicates a bull trap or a buying opportunity at the bottom of a long-term channel. Some are also drawing comparisons to Bitcoin and other altcoins, while others express skepticism.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

IMMX is trending due to a recently announced $100M upsized offering following positive ASH oral data, leading to community discussion around institutional validation and accelerated timelines. Investors are interpreting the upsized offering as a strong signal of confidence in IMMX's data and future prospects, despite short-term dilution concerns. The community is also discussing the potential for a buyout and the company's cash runway into 2027.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

The potential acquisition of Warner Bros. Discovery by Netflix is generating significant buzz, with community members weighing the pros and cons of the deal, including potential regulatory hurdles and debt implications. Some believe the move could solidify Netflix's dominance in the streaming market, while others worry about the impact on competition and content quality. Discussions also involve speculation around potential price movements and strategic advantages in the evolving media landscape.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

$PMV is trending due to its vibrant community and meme-driven culture, with many highlighting the coin's potential for significant growth and its energetic presence on social media. The community emphasizes the fun and engaging atmosphere surrounding the project, often referring to themselves as "infected" with the PumpMindVirus. Discussions also involve the token's association with the $PUMP ecosystem on the Solana blockchain.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

GPCR is trending as investors anticipate Phase 2 results for its oral GLP-1 candidate, with data expected soon. The community is weighing the potential impact of these results against competing therapies, particularly from VKTX, and discussing potential buyout scenarios. Community members are actively trading options, positioning themselves ahead of the data release.

CryingNTheCasino

The "No Crying In The Casino" narrative is resonating with the $TEARY community, as members emphasize the importance of holding strong and buying dips. Discussion highlights the project's community-driven utility and potential for long-term gains, with many expressing confidence in its future within the crypto space.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token is trending as a potential successor in the meme coin space, drawing comparisons to Doge and Pepe. The community is rallying behind the narrative of Yee as a long-term play within the ETH ecosystem, highlighting its strong community and potential for significant growth. Discussions include speculation around a 'meme prophecy' and a potential 'YEE vs PEPE' rivalry.

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar segment includes the design, development, manufacturing, and sales of an inverter solution designed to maximize power generation. The All Other segment includes the design, development, manufacturing and sales of UPS products, energy storage products, e-Mobility products, and automated machines. Its products and services include photovoltaic inverters, power optimizers, photovoltaic monitoring, software tools, and electric vehicle chargers. The company was founded by Guy Sella, Lior Handelsman, Yoav Galin, Meir Adest, and Amir Fishelov on August 7, 2006 and is headquartered in Herzliya, Israel.

Solaredge Technologies Inc

$SEDG is trending due to increased bearish sentiment and significant put option activity, suggesting investors are hedging against a potential downturn. The community is focused on the influence of a particular bearish trader (@unnconscious) and debates the stock's future direction. Broader uncertainty in the solar sector, policy risks, and a governance investigation may also be contributing to the stock's volatility.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic ($LUNC) is trending amid community discussions about potential price movements and burning mechanisms to reduce token supply. Some investors express optimism based on possible catalysts abroad and the potential for significant gains, while others remain skeptical, citing past crashes and market manipulation.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

AMRN is trending due to discussions around the NRDL (National Reimbursement Drug List) inclusion in China, with investors weighing the potential impact of non-inclusion on future revenue. Community talking points revolve around the company's strategy in China, the potential for a buyout, and the value of its assets. Some investors believe non-inclusion could strengthen Amarin's hand in pricing negotiations elsewhere, while others express frustration over the lack of company guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Traders await the September Core PCE report, the Fed’s preferred inflation gauge. Market odds still overwhelmingly point to a rate cut next week.</li><li>Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.</li><li>Retail chatter is driving sharp moves in names like SMX, SoFi, Rubrik, and Praxis.</li></ul>U.S. stock futures are trading modestly higher in early trade on Friday, suggesting a positive start for Wall Street. It follows a mixed session yesterday and is primarily driven by stronger anticipation of a Federal Reserve rate cut at the upcoming December FOMC meeting.Among crucial economic data to monitor, the&nbsp;September Core PCE Price Index data releases today, which is considered the Fed's preferred inflation gauge.&nbsp;According to the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">&nbsp;CME FedWatch tool</a>, the market is now pricing in an 87% chance of an interest rate cut next Wednesday, down from 90% a day earlier.As of 2:45 a.m. ET on Thursday, the Nasdaq 100 futures and S&amp;P 500 futures were up 0.4% and 0.2%, while the Dow futures and the Russell 2000 futures were flattish with a positive bias. On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and that toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, remained ‘bearish’ early Thursday.&nbsp;Stocks On Trending Watchlist&nbsp;Netflix (NFLX) is reportedly winning the bidding war for a major WBD deal, outbidding Paramount (PSKY). Keep an eye on Warner Bros.Discovery (WBD) stock as well.&nbsp;Security Matters (SMX) is the top-trending stock on Stocktwits as retail chatter rises over a potential short squeeze. Retail sentiment is trending in ‘extremely high’ territory. In other news, the company approved key proposals and re-elected directors at its annual general meeting in Dublin.SoFi Technologies (SOFI) slipped&nbsp;over 6% in after-hours trading after an equity offering. It is looking to raise $1.5 billion in a share sale as it diversifies beyond lending into other products.Apple (AAPL)&nbsp;remains on retail radar on news of executive transitions focused on AI and ongoing regulatory reviews of its App Store rules in Europe.Rubrik (RBRK) saw a significant after-hours pop after a surprise profit and stronger guidance tied to AI demand.Samsara (IOT)&nbsp;has gained retail traction post a strong Q3 earnings print.&nbsp;Wells Fargo raised the firm's price target to $52 from $50 and keeps an Overweight rating on the shares, while JPMorgan raised the firm's price target to $48 from $46 and keeps a Neutral rating.Candel Therapeutics (CADL) is on retail radar on Friday. The company is scheduled to hold&nbsp;an R&amp;D event at 11:00 am ET to detail the BLA roadmap for prostate cancer drug CAN-2409.Praxis Precision Medicines (PRAX)&nbsp;is also inching higher on Stocktwit’s trending list after positive results from the EMBOLD relutrigine study. The company also&nbsp;confirmed it has an upcoming meeting with the FDA to discuss the results and the path forward for a New Drug Application (NDA).&nbsp;Other stocks to keep on the watchlist post their earnings release in after-hours are&nbsp;Domo (DOMO), HP Enterprise (HPE), SentinelOne (S), and DocuSign (DOCU).Key Catalysts To Watch Out ForOn the economic front, investors will be watching for data on inflation and consumer health ahead of the Federal Reserve's final policy meeting of the year.<ul><li>September Core PCE Price Index (10:00 am ET)</li><li>September Personal Income/Spending Data (10:00 am ET)</li><li>December Michigan Consumer Sentiment (10:00 am ET)</li><li>Consumer Credit Change (3:00 pm ET)</li></ul>And on the earnings front, investors will be watching for Victoria’s Secret ($VSCO) pre-market, among others.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar

Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.

Equity

Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.


Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $24.00

Citigroup reduced their price target on shares of Candel Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday...

Candel Therapeutics (NASDAQ:CADL) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded shares of Candel Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Candel Therapeutics (NASDAQ:CADL) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Candel Therapeutics (NASDAQ:CADL - Get Free Report) posted its earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of...

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are presently covering the stock, Marketbeat.com...

Candel Therapeutics (CADL) on Tuesday said that it has entered into a five-year, $130 million term loan facility with Trinity Capital (TRIN).The loan facility <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166168/0/en/Candel-Therapeutics-Enters-into-130-Million-Term-Loan-Facility-with-Trinity-Capital-Inc.html">comprises</a> four tranches. While the first tranche of $50 million will be drawn upon closing of the agreement, the second and third tranche totaling $50 million will be available to draw on the achievement of certain milestones, and the fourth tranche of $30 million will be available at the lender’s discretion, the company said. The loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.Proceeds from the loan will be used to refinance certain loan and security agreements, as working capital, and to fund general corporate purposes. The company also said it intends to use the proceeds towards the initiation of a pivotal phase 3 clinical trial of its lead candidate CAN-2409 in non-small cell lung cancer in the second quarter of 2026.Candel Therapeutics shares traded 7% lower on Tuesday morning. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CADL">CADL stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Candel CFO Charles Schoch said that the strategic financing, in addition to the company’s cash and cash equivalents of $87.2 million as of September 30, strengthens the company’s balance sheet and is also expected to support the company through CAN-2409’s potential launch in early localized prostate cancer and into commercialization.The company plans to submit an application to the U.S. Food and Drug Administration (FDA) for the approval of CAN-2409 for prostate cancer in the fourth quarter of 2026.CADL stock is down by 31% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer 

The company said that the loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer Trinity Capital Inc. Provides $130 Million in...

Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know

Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

$SOFI

$RDDT

$CVNA

$MSTR

Which stock do you think gets added to the S&amp;P 500 in today’s rebalance?

Stocktwits

Which stock do you think gets added to the S&P 500 in today’s rebalance?

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CADL News

CADLCandel Therapeutics Inc